XXII 22nd Century Group Inc.

22nd Century Group (Nasdaq: XXII) to Expand VLN® Sales in Three Additional States: Arizona, Utah and New Mexico

22nd Century Group (Nasdaq: XXII) to Expand VLN® Sales in Three Additional States: Arizona, Utah and New Mexico

  • Combined with Ongoing Launch in Colorado, VLN® Will Be Available in All “Four Corners” States
  • Utah and New Mexico Join Colorado as VLN® States with Favorable MRTP Excise Tax Programs

BUFFALO, N.Y., Oct. 26, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: ), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced that the Company has further expanded on the previously announced launch of its VLN® reduced nicotine content cigarette products in Colorado with the addition of Arizona, Utah and New Mexico, collectively known as the “Four Corners” states.

22nd Century will leverage both existing partners and new distribution networks in the additional states to make its VLN® products available to adult smokers in these markets.

“We made clear that our statewide launch in Colorado and continued expansion in Illinois were just the first steps of our accelerated VLN® rollout. With the addition of three more states, we are moving ahead with our plans to rapidly make our innovative products available to a much larger portion of the adult smoker population in the United States,” said John J. Miller, president of 22nd Century’s Tobacco Business. “This is a massive market in need of new solutions to help adult smokers smoke less. Every 1% share of the U.S. market equates to approximately $800 million in sales at the register, which is about $500 million in revenue to a premium cigarette manufacturer.”

“These four states will demonstrate our scalable and repeatable state launch blueprint for VLN®, which we are now leveraging to rapidly put our product in front of an ever-growing population of adult smokers looking for a way to smoke less. Additionally, we have the benefit of favorable MRTP excise tax structures for tobacco products sold in Utah and New Mexico, similar to the beneficial programs in Colorado, that can assist us in getting the word out to adults who can benefit from our products,” said Miller. “Expanding into the Four Corners gives VLN access to not only those states, but also adjacent geographies with concentrated centers of adult smokers, allowing us to market VLN in a streamlined and efficient manner.”

22nd Century Group’s proprietary VLN® cigarettes smoke, smell, and taste like a cigarette but contain approximately 95% less nicotine than conventional cigarettes, a level shown to be non-addictive. As noted on the packaging, VLN® is the only cigarette in the world purposefully designed to “Help You Smoke Less.”

22nd Century Group’s Chicago pilot sales program demonstrated that in-store outreach was highly effective, and once adult smokers had tried VLN®, the vast majority were quick to recommend VLN® to other adult smokers. The Company is building out a network of partners and distribution resources to not only stock or distribute VLN®, but also support additional functions such as merchandising and product advice to expand the awareness of VLN®’s highly differentiated value proposition in key retail channels.

“VLN® is more than just a tool to help smokers smoke less,” said Miller. “With the increasing interest from state and local governments to ban flavoring agents and even menthol, adult smokers need products to help them transition away from highly addictive traditional cigarettes. With our FDA MRTP authorizations, VLN® King and VLN® Menthol King provide a clinically researched tool to help smokers reduce their smoking and a regulatory pathway for government policy makers to provide an exemption to assist menthol smokers in transitioning away from addictive traditional menthol cigarettes and advance important public health goals.”

About 22nd Century Group, Inc.

22nd Century Group, Inc. (Nasdaq: ) is a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. With dozens of patents allowing it to control nicotine biosynthesis in the tobacco plant, the Company has developed proprietary reduced nicotine content (RNC) tobacco plants and cigarettes, which have become the cornerstone of the  to address the widespread death and disease caused by smoking. The Company received the first and only FDA MRTP authorization of a combustible cigarette in December 2021. In tobacco, hemp/cannabis, and hop plants, 22nd Century uses modern plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products industries by creating new, proprietary plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits.

Learn more at , on , on , and on .

Learn more about VLN® at .

Cautionary Note Regarding Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 1, 2022, and in the Company’s Quarterly Report filed on August 9, 2022. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

Investor Relations & Media Contact

Mei Kuo

22nd Century Group, Inc.

Director, Communications & Investor Relations

Darrow Associates Investor Relations

Matt Kreps

T: 214-597-8200



EN
26/10/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on 22nd Century Group Inc.

 PRESS RELEASE

22nd Century Group (XXII) Acquires RX Pharmatech Ltd, Greatly Strength...

22nd Century Group (XXII) Acquires RX Pharmatech Ltd, Greatly Strengthening UK and EU Market Position Immediately Accretive Addition to the Hemp/Cannabis Business with Positive EBITDA 1,276 Novel Food Applications for Cannabinoid Products to Accelerate Growth in the U.K. and EU Food and Nutraceuticals Markets BUFFALO, NY, Jan. 24, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: ), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, today announced the acquisition of privately held RX ...

 PRESS RELEASE

22nd Century Group (XXII) Announces Filing of U.S. DMF (Drug Master Fi...

22nd Century Group (XXII) Announces Filing of U.S. DMF (Drug Master File) for CBD API; New Global Sales, Marketing and Distribution Agreement with Transo-Pharm for Cannabinoid APIs Partnership Will Provide Pharmaceutical Grade Cannabinoid Active Ingredients to the Largest Pharmaceutical and Consumer Goods Names in the Industry BUFFALO, N.Y., Jan. 23, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: ), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, today announced filing of a U.S. ...

 PRESS RELEASE

22nd Century Group’s GVB Biopharma Opens New Central Distribution Faci...

22nd Century Group’s GVB Biopharma Opens New Central Distribution Facility in The Netherlands New distribution facility supports rapidly growing demand for hemp/cannabis products BUFFALO, N.Y., Nov. 16, 2022 (GLOBE NEWSWIRE) -- , a 22nd Century Group company (Nasdaq: ), today announced that it has opened a new, strategically-located distribution facility in the Netherlands to support its growing business in Europe, the Middle East, and Africa (EMEA). The new distribution facility will increase existing and new customer access to GVB’s quality hemp/cannabis products, speed up transaction...

 PRESS RELEASE

22nd Century Group (Nasdaq: XXII) GVB Biopharma to Exhibit at MJBizCon...

22nd Century Group (Nasdaq: XXII) GVB Biopharma to Exhibit at MJBizCon in Las Vegas BUFFALO, N.Y., Nov. 15, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: ), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced that the Company’s GVB Biopharma business will attend and be an exhibitor at MJBizCon in Las Vegas on November 16 to 18, 2022. “We’re excited to be exhibiting at MJBizCon for the fourth year, and this time with the combined GVB and 22nd Century team...

 PRESS RELEASE

22nd Century Group (Nasdaq: XXII) to Participate in November 2022 Inve...

22nd Century Group (Nasdaq: XXII) to Participate in November 2022 Investor Conferences BUFFALO, N.Y., Nov. 14, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: ), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced that the Company will be participating in the following investor conferences: On Tuesday, November 15, 2022, the Company will host one-on-one meetings at the Roth 2nd Annual AgTech Answers Event.On Thursday, November 17, 2022, the Company will ho...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch